Yili Chuanning Biotechnology (301301)2023-04-03 16:00Financial Performance - The company's operating revenue for 2022 was ¥3,820,657,857.71, an increase of 18.21% compared to ¥3,232,014,638.04 in 2021[11]. - The net profit attributable to shareholders for 2022 was ¥411,518,024.65, representing a significant increase of 269.58% from ¥111,346,659.27 in 2021[11]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥446,630,289.76, up 147.15% from ¥180,710,589.01 in 2021[11]. - The company's cash flow from operating activities for 2022 was ¥691,638,049.25, a decrease of 13.89% compared to ¥803,211,175.51 in 2021[11]. - The basic earnings per share for 2022 was ¥0.21, a 250.00% increase from ¥0.06 in 2021[11]. - The total assets at the end of 2022 were ¥10,390,399,359.24, reflecting a growth of 9.82% from ¥9,461,536,586.60 at the end of 2021[11]. - The net assets attributable to shareholders at the end of 2022 were ¥6,204,485,260.20, an increase of 30.04% from ¥4,771,284,144.72 at the end of 2021[11]. - The company achieved a total revenue of 606.76 million CNY for the reporting period[147]. - The total operating income of the evaluated units accounted for 97.74% of the company's consolidated financial statement operating income[165]. Dividend Policy - The company plans to distribute a cash dividend of 0.93 CNY per 10 shares to all shareholders, based on a total of 222,280,000 shares[2]. - The net profit attributable to shareholders reached RMB 412 million, a significant increase of 269.58% compared to the previous year[55]. - The company achieved a net profit attributable to shareholders of 411,518,024.65 CNY for the year 2022, with a profit distribution plan proposing a cash dividend of 0.93 CNY per 10 shares, totaling 206,720,400.00 CNY, which represents 50.23% of the net profit[161]. - The total distributable profit at the end of 2022 was 666,044,232.52 CNY, with retained earnings of 459,323,832.52 CNY to be carried forward for future distribution[161]. - The company has committed to a three-year dividend return plan to actively reward investors and protect the rights of minority shareholders[158]. Research and Development - The company reported a significant focus on research and development, with potential risks including industry policy changes and market risks[2]. - The company has established a comprehensive synthetic biology platform that includes a computational biology strain design platform and an automated high-throughput strain construction and screening platform, significantly improving R&D efficiency[31]. - The total R&D investment for 2022 was ¥35,381,740.73, accounting for 0.93% of operating revenue, a decrease from 1.41% in 2021[77]. - Research and development expenses increased by 7.37% to ¥35,381,740.73, indicating ongoing investment in innovation[72]. - The number of R&D personnel increased to 132 in 2022, representing a growth of 6.45% compared to 124 in 2021[76]. - The company is advancing several R&D projects aimed at enhancing product lines and market competitiveness, including the development of 7-ADCA through biotechnological methods[73]. Market Position and Strategy - The company holds a 43.86% market share in the thiocyanate erythromycin market, with an annual production capacity of approximately 3,000 tons, ranking second in the industry[25]. - In the cephalosporin intermediate market, the company has a total production capacity of about 3,000 tons per year, with a market share of 37.00%, making it the industry leader[25]. - The company's penicillin intermediate production capacity is approximately 6,700 tons per year, holding an 18.00% market share, ranking second in the industry[25]. - The company is positioned as a leading enterprise in the antibiotic intermediate market, benefiting from a robust industrial production system[25]. - The company aims to transition from resource-driven to technology-driven growth, enhancing its operational efficiency and market competitiveness[33]. Governance and Compliance - The company has established a strong governance structure with a board of directors and supervisory board ensuring accountability[3]. - The board of directors consists of 7 members, including 3 independent directors, and held 6 meetings during the reporting period[113]. - The company has established several engineering technology centers and has been recognized as a model for green manufacturing and intelligent manufacturing[39]. - The company has a clear and complete asset ownership structure, with no reliance on the controlling shareholder or related entities[123]. - The company has established an independent financial department and maintains a separate bank account, ensuring no shared accounts with the controlling shareholder[126]. Environmental Responsibility - The company has invested nearly 2.5 billion yuan in environmental protection facilities, accounting for over 25% of total project investment[49]. - The company has developed a project for the regeneration of saturated granular activated carbon, utilizing clean fuel biogas from its wastewater treatment system[176]. - The company has established multiple environmental management systems to ensure effective waste treatment and compliance with environmental standards[169]. - The company is actively responding to national carbon peak and carbon neutrality goals, establishing a greenhouse gas emission management system[176]. - The company has implemented strict environmental standards and continuously increases investment in environmental protection[179]. Risk Management - The company has a comprehensive risk management strategy to address environmental, quality control, and innovation risks[2]. - The company aims to mitigate foreign exchange risks through hedging strategies, ensuring compliance with relevant regulations and internal controls[89]. - The risk control measures include avoiding speculative trading and focusing on hedging to protect against significant currency fluctuations[89]. - The company has established a management system for foreign exchange hedging, detailing operational procedures, approval authority, and risk reporting mechanisms[89]. Investment and Financing - The total amount of funds raised in the IPO was RMB 1,114 million, with a net amount of RMB 1,021 million after deducting expenses[90]. - The company has committed to invest RMB 60 million in projects, with RMB 40 million already utilized for repaying bank loans, achieving a 100% investment progress[92]. - The financing activities generated a net cash flow of ¥475,923,386.14, a significant increase of 163.52% compared to the previous year, primarily due to public share issuance[78]. Community Engagement - The company actively supports rural revitalization by purchasing local agricultural products, employing over 40 villagers from the Yingyeer Village[185]. - The company has participated in the "Hundred Enterprises Help Hundred Villages" initiative, focusing on practical assistance and job creation for local residents[185]. - The company has made significant contributions to poverty alleviation efforts in Xinjiang, enhancing social stability and economic development[185].